European pharma Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
12:19
Jan 28
Jan 28
Weak dollar, IRA pressure pharma.
European pharma faces pressure from U.S. IRA drug-price negotiation, profit-taking after a strong run, and a weaker dollar that hurts companies reporting in U.S. dollars. The weaker dollar is generally a headwind for pharma.
MED
09:48
Jan 27
Jan 27
EU-India FTA aids European export sectors
The EU-India free trade agreement concluded after nearly two decades and will eliminate or reduce tariffs on 96.6% of EU goods exported to India. The EU claims the deal will double EU goods exports to India by 2032. This should improve market access for European exporters, especially carmakers and car parts makers (auto tariffs cut from up to 110% to as low as 10%, car part tariffs abolished), machinery (44% tariffs cut), chemicals (22%), pharma (11%), wine (150% down to 75%, eventually 20%), and olive oil (45% to 0%). Tariffs phase in over five to ten years and the deal still needs European Council and Parliament approval, so it is a developing positive catalyst rather than an immediate clean trade.
MED
12:24
Jan 26
Jan 26
Pharma catalysts support reasonable valuations.
Pharma is growing 5-6% this year with reasonable valuations and catalysts from oral Wegovy data and Lilly's oral equivalent; the sector is already one of Europe's best performers.
MED
About European pharma Investor Commentary
Across the available history and selected sources, Buzzberg tracks European pharma across 1 sources: 1 bullish vs 0 bearish calls from 3 authors. Historical directional balance: 33% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 3 total trade ideas tracked. Latest voices: Sam Fazeli, Oliver Crook, Rod Turnbull.